A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients
Phase of Trial: Phase I/II
Latest Information Update: 03 Jul 2018
At a glance
- Drugs ACIT 1 (Primary)
- Indications Pancreatic cancer; Tumours
- Focus Adverse reactions
- Sponsors Cancer Vaccines Limited
- 28 Jun 2018 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.
- 28 Jun 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.
- 10 Apr 2017 Status changed from not yet recruiting to recruiting.